Author/Authors :
Soleimani Mohammad نويسنده Davudi N , Alemi Mohsen نويسنده Fertility-Infertility Research Center, Urology and Nephrology Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermansh , Azizi Jalilian Farid نويسنده Dept. of Medical Microbiology, Ilam University of Medical Sciences, Ilam, Iran , Bashiri Arefeh نويسنده Department of Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran , Haghighat Ghazaleh نويسنده Department of Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
Abstract :
PSA is the most routine marker to detect prostate cancer, but due to its low specificity that can lead to a number of unnecessary biopsies, there is great need for an alternate method. Can PCA3 be one of these methods? PCA3 is overexpressed in prostate cancer, not in benign conditions such as prostatitis (unlike PSA). Because of its efficacy (being more sensitive and specific in comparison with PSA), this biomarker could be a very useful and promising method for the early detection of prostate cancer, especially in combination with other tests such as TMPRSS2-ERG gene fusion.
